These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10961441)

  • 1. Clinical experience with Cerebrolysin.
    Molloy DW; Standish TI
    J Neural Transm Suppl; 2000; 59():293-300. PubMed ID: 10961441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
    Guekht AB; Moessler H; Novak PH; Gusev EI;
    J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages].
    Roshchina IF; Gavrilova SI; Zharikov GA; Kalyn IaB; Kolykhalov IV; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):52-5. PubMed ID: 15704485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
    Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H
    Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrolysin in Alzheimer's disease.
    Antón Álvarez X; Fuentes P
    Drugs Today (Barc); 2011 Jul; 47(7):487-513. PubMed ID: 22013558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
    Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E
    Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease.
    Wei ZH; He QB; Wang H; Su BH; Chen HZ
    J Neural Transm (Vienna); 2007; 114(5):629-34. PubMed ID: 17318304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic results with Cerebrolysin in the treatment of dementia.
    Rainer M; Brunnbauer M; Dunky A; Ender F; Goldsteiner H; Holl O; Kotlan P; Paulitsch G; Reiner C; Stössl J; Zachhuber C; Mössler H
    Wien Med Wochenschr; 1997; 147(18):426-31. PubMed ID: 9408984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin.
    Alvarez XA; Sampedro C; Cacabelos R; Linares C; Aleixandre M; García-Fantini M; Moessler H
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):867-72. PubMed ID: 19531281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.
    Rüther E; Ritter R; Apecechea M; Freytag S; Gmeinbauer R; Windisch M
    J Neural Transm (Vienna); 2000; 107(7):815-29. PubMed ID: 11005546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
    Gavrilova SI; Kolykhalov IV; Korovaĭtseva GI; Zharikov GA; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):27-34. PubMed ID: 15880838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].
    Vereshchagin NV; Suslina ZA; Timerbaeva SL; Kashina EM; Gnezditskiĭ VV; Maksimova MIu; Rebrova OIu; Smirnova IN
    Ter Arkh; 2001; 73(4):22-7. PubMed ID: 11494441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of prolonged therapy of vascular dementia].
    Klin Med (Mosk); 2011; 89(5):57-60. PubMed ID: 22242270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.
    Muresanu DF; Alvarez XA; Moessler H; Novak PH; Stan A; Buzoianu A; Bajenaru O; Popescu BO
    J Neurol Sci; 2010 Dec; 299(1-2):179-83. PubMed ID: 20923712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study.
    Chen CC; Wei ST; Tsaia SC; Chen XX; Cho DY
    Br J Neurosurg; 2013 Dec; 27(6):803-7. PubMed ID: 23656173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin.
    Ruether E; Alvarez XA; Rainer M; Moessler H
    J Neural Transm Suppl; 2002; (62):265-75. PubMed ID: 12456069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrolysin: a review of its use in dementia.
    Plosker GL; Gauthier S
    Drugs Aging; 2009; 26(11):893-915. PubMed ID: 19848437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin.
    Muresanu DF; Rainer M; Moessler H
    J Neural Transm Suppl; 2002; (62):277-85. PubMed ID: 12456070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.
    Allegri RF; Guekht A
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The experience with endolumbar application of cerebrolysin in hemispheric ischemic stroke].
    Vilenskiĭ BS; Odinak MM; Shirokov EA; Vozniuk IA; Semenova GM; Grinevich TV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(11):31-4. PubMed ID: 11247183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.